北京师宏药业

Beijing Shihong Pharmaceutical is a prominent Chinese life sciences company dedicated to the research, development, and commercialization of radiopharmaceuticals. Established in 1998 and rooted in the academic expertise of Beijing Normal University, the company has become a key provider of diagnostic and therapeutic nuclear medicine products in China. Their portfolio includes Technetium-99m generators, various SPECT imaging kits for bone and myocardial scans, and Iodine-131 solutions for thyroid conditions. Shihong operates advanced, GMP-certified manufacturing facilities specifically designed for the handling of radioactive materials. The company is actively expanding its pipeline to include next-generation PET tracers targeting prostate cancer and neurological disorders. Through its specialized distribution network, Shihong supports hospitals and medical centers across the country, playing a vital role in the Chinese molecular imaging landscape.